Anavex Life Sciences CORP

Anavex Life Sciences announced plans to refresh its Board of Directors by nominating two new independent directors and urged stockholders to reject a control attempt by PVG Asset Management Corporation and Patrick S. Adams.

Anavex Life Sciences announced preliminary financial results for its second fiscal quarter ended March 31, 2026, alongside a strategic update focusing on its lead compound ANAVEX2-73 for CNS diseases.

Anavex Life Sciences Corp. has submitted a compliance plan to Nasdaq to regain listing compliance after failing to file its Q1 2026 financial report on time.

Anavex Life Sciences Corp. has scheduled its 2026 Annual Meeting for September 24, 2026, and established a July 10 deadline for stockholder proposals.

Anavex Life Sciences has received a Nasdaq delinquency notice due to a delay in filing its Form 10-Q for the quarter ended March 31, 2026.

Anavex Life Sciences Corp. announces the departure of Chief Operating Officer Felix Lauscher following a corporate reorganization.

Anavex Life Sciences reported a reduced net loss in Q1 2026, bolstered by a $36.3 million equity raise, while its Alzheimer's drug, blarcamesine, faces an EMA re-examination after a negative trend-vote.

Anavex Life Sciences Corp. reported an increased net loss for Q3 2025, alongside significant progress in its Alzheimer's and schizophrenia clinical programs and new capital raising initiatives.

Anavex Life Sciences Corp. files its 10-Q report for the quarter ended March 31, 2025, detailing financial results and providing updates on its clinical development programs.

Anavex Life Sciences Corp. reports a net loss for Q1 2025, alongside updates on its clinical trials for ANAVEX2-73 and ANAVEX3-71.

Anavex Life Sciences Corp. released its Q3 2024 financial results, detailing ongoing clinical trials and financial status.

Anavex Life Sciences Corp. released its financial results for the second quarter of 2024, alongside updates on its clinical development programs.

Anavex Life Sciences reports a negative trend vote from the EMA for its Alzheimer's drug blarcamesine, alongside increased net losses and decreased cash reserves for fiscal year 2025.

Anavex Life Sciences Corp. files its annual report, highlighting clinical trial progress, regulatory submissions, and financial results for the fiscal year ended September 30, 2024.

ANAVEX LIFE SCIENCES CEO Christopher U. Missling's stock options for 125,000 shares vested following the achievement of a key performance milestone related to blarcamesine's regulatory dialogue.

ANAVEX LIFE SCIENCES CORP.'s Principal Financial Officer, Sandra Boenisch, saw 12,500 stock options vest following the achievement of a key regulatory milestone for blarcamesine.

ANAVEX Life Sciences' PFO & Treasurer, Sandra Boenisch, saw 12,500 stock options vest following the successful readout of the AV3-71-SZ-001 schizophrenia study.

ANAVEX LIFE SCIENCES CORP. CEO Christopher Missling's stock options for 125,000 shares vested following the successful readout of the AV3-71-SZ-001 schizophrenia study.

Anavex Life Sciences Corp.'s President and CEO, Christopher U. Missling, exercised 187,500 stock options, resulting in a net acquisition of 42,452 shares after tax withholdings.

ANAVEX LIFE SCIENCES CORP.'s PFO & Treasurer, Sandra Boenisch, saw 12,500 stock options vest following the achievement of a key preclinical data publication milestone.

Anavex Life Sciences Corp. has filed a definitive proxy statement with the SEC.

Anavex Life Sciences is asking stockholders to approve an amendment to its 2022 Omnibus Incentive Plan, including increasing the number of shares available and establishing a minimum vesting period.

ANAVEX Life Sciences Corp. has filed a definitive proxy statement with the SEC.

Anavex Life Sciences Corp. has released its proxy statement outlining the agenda and procedures for its 2024 Annual Meeting of Stockholders, scheduled for June 18, 2024.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Anavex Life Sciences Corp. common stock as of June 30, 2026.

The Vanguard Group filed an amendment to its Schedule 13G for Anavex Life Sciences Corp., reporting zero beneficial ownership following an internal realignment.